MAP2K7 and melanoma: Melanoma, a skin cancer with an extremely high mortality rate, is a serious health concern both in the United States and worldwide,1 and its incidence is increasing.2 Recently, new therapies such as molecular‐targeted therapy (BRAF inhibitors3 and MEK inhibitors4), immunotherapy (Ipilimumab5 and PD‐1 inhibitors6) or oncolytic virus therapy (talimogene laherparepvec,7 the only oncolytic virus having gained FDA approval for melanoma treatment, which is designed to induce lysis of tumor cells) have emerged.